NCT01814748View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

PHASE3CompletedINTERVENTIONAL

Enrollment

203

Participants

Timeline

Start Date

May 3, 2013

Primary Completion Date

September 14, 2015

Study Completion Date

September 14, 2015

Conditions

Diabetes Mellitus

Interventions

DRUG

Omarigliptin

Omarigliptin 25 mg capsule administered orally once weekly

DRUG

Placebo to omarigliptin

Matching placebo to omarigliptin 25 mg capsule administered orally once weekly

DRUG

Metformin

Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01814748 - A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) | Biotech Hunter | Biotech Hunter